ClinicalTrials.gg
RecruitingNCT06356220GF-NOURISHUpdated Nov 2, 2026

GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)

An interventional study of Gluten-Free Diet Education in Celiac Disease in Children and Nutrition Disorder, Child, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 2, 2026Study contact changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Child Nutrition Disorders with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Child Nutrition Disorders · United States.

Planned enrollment
7th of 14
120 · median 120
Started
2025
the only one that year
No phase
10 of 15
2 open now
Registered
13th of 15
by date
Lead sponsor
2 of 15
Boston Children's Hospital

Among the 15 studies in Child Nutrition Disorders with a site in United States, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 13th registered.

Child Nutrition Disorders

168 studies on the registry are indexed under Child Nutrition Disorders; 34 are open to participants now.

Browse Child Nutrition Disorders studies →

Open to participants now

3 of the 15 studies in Child Nutrition Disorders with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Child Nutrition Disorders studies recruiting now, 3 (13%) set no upper age limit and 20 (87%) stop at 75 or younger; 19 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Child Nutrition Disorders with a site in United States, or all of them as a file.
02

Study summary

The investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. The investigators hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits

Read the detailed description

Celiac Disease (CeD) is a gluten driven enteropathy that affects up to 3% of the population and typically develops in childhood. Lifelong adherence to a gluten-free diet (GFD) is the primary treatment. Rice, the most common gluten-free substitute grain, naturally bioaccumulates inorganic arsenic. Chronic arsenic exposure may affect neurodevelopment, increase risk of cardiovascular disease and cause kidney damage. In a prior prospective cohort study, the investigators demonstrated that urine arsenic levels increased 2-3 times in newly diagnosed children 6 months after adoption of a GFD. This likely is a consequence of both impaired absorption of vitamin B12 and folate in the small intestine (both nutrients are part of the pathway to excrete arsenic from the body) and increased ingestion of rice products on a gluten-free diet. In particular, gluten-free ultra-processed free foods tend to be specialty products that are made predominantly from rice products, easy for families to identify as safe when avoiding gluten, and rarely fortified with vitamins. Ultra-processed food(UPF) consumption has also been associated with lower perceived quality of life in patients with CeD.

Given the risks associated with gluten-free ultra-processed food, the investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. The investigators hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits

The investigators propose to randomize (1:1) 120 children at celiac disease diagnosis to either a novel nutritional education (GF-NOURISH) focused on minimizing ultra-processed gluten free foods or to a conventional GFD nutritional education. Urine/Hair/Toenail arsenic, changes in percent fat free mass, household budgets, diet quality measurements will be evaluated after 6 months on the GFD.

03

Conditions studied

  • Celiac Disease in Children
  • Nutrition Disorder, Child
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 2-18 years of age with recent celiac disease diagnosis

Exclusion criteria

Exclusion Criteria:

  • Allergic to \<3 of the top 8 food allergens
  • Co-morbid conditions treated with dietary modifications or that influence nail arsenic values
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    GFFG

    Our Canadian collaborators have created Gluten Free-Food Guide (GFFG), a validated nutritional educational intervention, which targets increasing consumption of natural gluten free foods and limiting UPFs. However, this intervention has not yet been applied to a pediatric cohort in the United States. Preliminary data demonstrate enrollment feasibility and generalizability of the intervention. The GFFG arm will have increased focus on plant proteins, minimally processed food intake and fruit/vegetable intake with emphasis on naturally gluten-free foods. The GFFG class will highlight that not all gluten-free foods have the same nutritional and health benefits.

    Other: Gluten-Free Diet Education

  • Active comparator
    Conventional GFD Nutrition Education

    Diet counselling in both the conventional GFD nutrition education and the GFFG intervention arm will include concepts related to nutrition literacy (food label reading, gluten identification, nutritional adequacy). The control group will be provided with the GFFG at the end of the study.

    Other: Gluten-Free Diet Education

Interventions

  • OtherGluten-Free Diet Education

    The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .

06

What researchers measure

Primary outcomes

  1. To compare the effect of GFFG versus conventional GFD class on body composition, specifically fat free mass

    While the gold standard measurement for body composition is dual energy X-ray absorptiometry (DEXA) or underwater weighing and air displacement plethysmography (BodPod), these techniques require special facilities that increase cost, are difficult to perform in outpatient settings. DEXA scans also involve radiation exposure. Therefore, the investigators will use bio-impedance spectroscopy analysis (BSA), which is a simple, noninvasive, reproducible, portable and convenient method to measure body composition.26 BSA utilizes body resistance and reactance to derive phase angle (PhA) and estimate the fat (FM) and non-fat (FFM) components of the body

    Time frame: Over 6 months

Secondary outcomes

  1. To compare the effect of GFFG vs conventional GFD class on diet quality

    Given that one of primary objectives of the GFFG is to decrease ultra-processed gluten-free foods (UPGFF), this aim focuses on assessing the impact of the nutrition education intervention on participant's recorded UPF consumption and diet quality. All participants will fill out a three-day food frequency record at study entry and six months of GFD. Food items will be classified by the NOVA system: the most used identification system for UPFs. Of the four leading food processing-based classification systems (NOVA, IARC(International Agency for Research on Cancer), IFIC(International Food Information Council) and UNC(University of North Carolina)), NOVA has been used in 95% of studies on consumption of highly processed foods and chronic health outcome published between 2015 and 2019 in children and adults. NOVA categorizes all the foods by level of food processing: i) unprocessed or minimally processed, (ii) processed culinary ingredients, (iii) processed foods and (iv) UPFs.

    Time frame: Over 6 months

  2. To compare the effect of GFFG versus conventional GFD on arsenic exposure

    The outcome is nail arsenic level after six months on GFD. Toenails will be stored at room temperature and are stable as heavy metals naturally bind to keratin. Toenails will be cleaned to remove exogenous contamination, and then, acid digested.

    Time frame: Over 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.

Of 83 non-industry interventional studies with no phase under Child Nutrition Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 25 months is above that.

Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Aug 2026 → May 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 10, 2024
StartActual
Apr 29, 2025
Primary completionEst.
May 2027was Aug 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→May 2027
Oct 20, 2026
Study completion
Dec 2026→Jun 2027
Oct 20, 2026
Contact
Study contact now listed: added n•••@childrens.harvard.edu · •••6058. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Boston Children's Hospital · Boston, United StatesContact l•••@childrens.harvard.edu · •••6000→n•••@childrens.harvard.edu · •••6000
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Contact Study contact now listed: added n•••@childrens.harvard.edu · •••6058. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Boston Children's Hospital · Boston, United StatesContact l•••@childrens.harvard.edu · •••6000→n•••@childrens.harvard.edu · •••6000
  2. Oct 20, 2026
    Primary completion Aug 2026→May 2027
    Study completion Dec 2026→Jun 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06356220
Responsible party
Nan Du (Instructor, Attending, Boston Children's Hospital) — Principal investigator
First posted
Apr 10, 2024
Start date
Apr 29, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Nan Du, MD, MPH
Contact
nan.du@childrens.harvard.edu
617-355-6058

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion